Sera Prognostics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Sera Prognostics şirketinin kazançlarının yıllık 4.5% oranında düşmesi, yıllık gelirinin ise yıllık 125.3% oranında artması bekleniyor. EPS'nin yıllık 1.8% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-4.5%

Kazanç büyüme oranı

-1.8%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	125.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	08 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Oct 03

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Jun 15

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Feb 16

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Nov 03

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Aug 10

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Jul 21

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Apr 06

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Dec 15

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:SERA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	18	-36	N/A	N/A	1
12/31/2025	5	-33	N/A	N/A	2
12/31/2024	0	-32	N/A	N/A	2
9/30/2024	0	-32	-16	-15	N/A
6/30/2024	0	-32	-16	-15	N/A
3/31/2024	0	-34	-18	-17	N/A
12/31/2023	0	-36	-27	-27	N/A
9/30/2023	0	-38	-28	-28	N/A
6/30/2023	0	-42	-29	-29	N/A
3/31/2023	0	-43	-31	-30	N/A
12/31/2022	0	-44	-35	-35	N/A
9/30/2022	0	-47	-38	-37	N/A
6/30/2022	0	-46	-38	-37	N/A
3/31/2022	0	-41	-36	-34	N/A
12/31/2021	0	-35	-33	-32	N/A
9/30/2021	0	-28	-27	-27	N/A
6/30/2021	0	-23	-22	-21	N/A
3/31/2021	0	-22	-19	-19	N/A
12/31/2020	0	-20	-17	-17	N/A
12/31/2019	0	-17	-19	-19	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SERA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SERA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SERA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SERA şirketinin gelirinin (yıllık 125.3% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SERA şirketinin gelirinin (yıllık 125.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SERA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Sera Prognostics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus revenue estimates decrease by 55%, EPS upgraded

Price target decreased to US$7.00

Consensus forecasts updated

Recent updates

Sera Prognostics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Sera Prognostics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Sera Prognostics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn

Sera Prognostics Inc. Announces Publication of Positive AVERT Trial Results in the International Peer-Reviewed Journal, Diagnostics

Chief Data Officer recently sold US$86k worth of stock

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)

Sera Prognostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Sera Prognostics, Inc., Annual General Meeting, Jun 06, 2024

Chief Scientific Officer notifies of intention to sell stock

President recently sold US$364k worth of stock

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Sera Prognostics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

President recently sold US$225k worth of stock

Sera Prognostics: The Pregnancy Company On A Hot Streak

Independent Chairman notifies of intention to sell stock

General Counsel recently sold US$52k worth of stock

New major risk - Share price stability

Sera Prognostics Inc. Announces Preliminary Efficacy Met in Pivotal Prime Study Interim Look - Enrollment to Stop Due to Success

Consensus revenue estimates decrease by 14%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sera Prognostics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 55%, EPS upgraded

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Sera Prognostics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Market cap size

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Sera Prognostics, Inc. Announces Resignation of Nadia Altomare from the Position of Chief Commercial Officer of the Company, Effective as of June 9, 2023

Sera Prognostics, Inc. Announces Board Changes

First quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings: Revenues miss analyst expectations

Sera Prognostics, Inc. Announces Positive Top-Line Data from AVERT PRETERM TRIAL

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Sera Prognostics, Inc. Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the Pretrm® Test-And-Treat Strategy Across Diverse Populations

Insufficient new directors

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Sera Prognostics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$7.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Sera Prognostics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Chief Scientific Officer notifies of intention to sell stock

Sera Prognostics Appoints Jane Barlow to Nominating and Governance Committee

Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from Russell 2500 Value Index

Sera Prognostics, Inc. Announces Publication of Data Demonstrating Improved Performance of its PreTRM Test with More Precise Gestational Age

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sera Prognostics, Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Sera Prognostics, Inc., Annual General Meeting, Jun 03, 2022

Sera Prognostics, Inc Appoints Jane F. Barlow as Director to the Board to Serve as Class I Director

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Scientific Officer exercised options to buy US$282k worth of stock.

Insufficient new directors

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Sera Prognostics Inc. Announces Pricing for PreTRM® Test, the Only Broadly Validated Blood Test to Assess Risk of Preterm Birth

Third quarter 2021 earnings released: US$0.39 loss per share

Sera Prognostics, Inc. Announces Publication of Health Economic Analysis Supporting Pretrm Test-And-Treat Strategy to Improve Maternal and Infant Health

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin